Stocks avoid Centoxin bloodbath

Centoxin redux didn't seem to reverberate as much as it could have through the offerings market, despite early-in-the-week jitters that suspension of Centocor's sepsis trial could turn off the spigot.

A resentful mood percolated among companies and on Wall Street, unhappy that the sector had to go through negative news on the same product twice. Bear, Stearns analyst David Molowa summed up the feelings. "It's bad enough it blew the market the first time," he said, "but to have to go through it a